RO5126766 clinical trials
Also written Avutometinib, VS-6766 and RO5126766.
Counted the way a researcher would: RO5126766 with its salts, dosage forms, brands and biosimilars. Looking for a trial to join? Including related medicines shows more you could take part in.
This browser remembers your choice.
How each study uses RO5126766 is sorted by a rule, right about nine times in ten. Readers can ask us to read every study one by one.Ask us to read each study
Get an email when these change. Save the RO5126766 studies recruiting or about to start — once a week, free: studies that open, close, add sites or post results.
See an example email
Example · made-up studies
Breast cancer · Recruiting: 2 came in, 3 changed
What changed in your alerts, Oct 31 – Nov 6:
A study of drug A after surgery for early breast cancer
Came in · now Recruiting
Drug B with hormone therapy in advanced breast cancer
Changed
· Sites: 4 added, including Seoul and Busan
· Enrollment: 300 → 450 participants
Exercise during chemotherapy
Now Active, not recruiting
One email a week for all your alerts. Stop any time.
Approvals
The first approval found in each region, with its record
- United States
- Not in FDA's approval records
- European Union
- Not in EMA's list of EU-wide authorizations
From FDA's Drugs@FDA and Purple Book (through openFDA) and the European Medicines Agency, files of Sept 2026 and 27 Oct 2026. National approvals in Europe and other countries are not included. How this is worked out
How studies write it
Studies that test it under each name
Studies by the year they started
28 studies that test it; most in 2023 (7); 1 more planned to start later
| Year | Studies |
|---|---|
| 2008 | 1 |
| 2013 | 1 |
| 2017 | 1 |
| 2018 | 1 |
| 2020 | 1 |
| 2021 | 2 |
| 2022 | 3 |
| 2023 | 7 |
| 2024 | 7 |
| 2025 | 1 |
| 2026 | 3 |
By phase
A phase 1/2 study counts in both.
What it is tested for
Each study’s main condition, where its own words name it, so a study counts once.
Who runs them
Industry 8 · Other 21
Verastem, Inc. (7) · Memorial Sloan Kettering Cancer Center (5) · Institute of Cancer Research, United Kingdom (2) · Emory University (2) · M.D. Anderson Cancer Center (2) · Royal Marsden NHS Foundation Trust (1) · Hoffmann-La Roche (1) · Girish Dhall, MD (1)
Often tested with
Tested in the same studies.
Defactinib (15) · Cetuximab (2) · Sotorasib (1) · Avutometinib and Defactinib (1) · Letrozole (1) · Everolimus (1) · Defactinib hydrochloride (1)
Related medicines
As reviewed, each with the page that says it.
- One of Protein Kinase Inhibitors source
Coming up
From the study records. Dates are the sponsors’ own estimates and often move.
Reaching primary completion within a year · 4
Studies that test RO5126766.
- Dec 2026Identification of Treatment Concentrations of Defactinib or VS-6766 for the Treatment of Patients With GlioblastomaEarly Phase 1 · Emory University
- Mar 2027A Study of Avutometinib (VS-6766) and Defactinib in People With Mesonephric Gynecologic CancerPhase 2 · Memorial Sloan Kettering Cancer Center
- Apr 2027A Study of Avutometinib, Defactinib, and Letrozole in People With Low-Grade Serous Ovarian CancerPhase 2 · Memorial Sloan Kettering Cancer Center
- Aug 2027A Study of Avutometinib and Defactinib in People With Thyroid CancerPhase 2 · Memorial Sloan Kettering Cancer Center
Studies
Open first, then newest update. How each study uses RO5126766 is read from its arms, and is right about nine times in ten. Ask us to read each study. These are the studies that list it as an intervention; a search of ClinicalTrials.gov also finds studies that mention it only in a description, such as earlier treatment.
Testing it · 29
- Avutometinib and Defactinib in Diffuse Gastric CancerRecruitingPhase 2Ryan H. Moy, MD, PhDNCT06487221Written as AvutometinibHow we know
- A Study of Avutometinib (VS-6766) + Defactinib (VS-6063) in Recurrent Low-Grade Serous Ovarian CancerRecruitingPhase 3Verastem, Inc.NCT06072781Written as avutometinibHow we know
- Combination of Avutometinib and Defactinib for Treatment of Relapsed, Refractory, Metastatic, or Unresectable Malignant Peripheral Nerve Sheath TumorNot yet recruitingPhase 2Girish Dhall, MDNCT07743554Written as avutometinib capsule + defactinib tabletHow we know
- A Study of Avutometinib, Defactinib, and Letrozole in People With Low-Grade Serous Ovarian CancerRecruitingPhase 2Memorial Sloan Kettering Cancer CenterNCT06394804Written as AvutometinibHow we know
- A Study of Avutometinib and Defactinib in People With Thyroid CancerRecruitingPhase 2Memorial Sloan Kettering Cancer CenterNCT06007924Written as AvutometinibHow we know
- Open-label Phase 2 Study of Avutometinib (RAF/MEK Clamp) in Combination With Defactinib (FAK Inhibitor) and Cetuximab in Patients With Unresectable, Anti-EGFR-Refractory Advanced Colorectal CancerRecruitingPhase 2M.D. Anderson Cancer CenterNCT06369259Written as AvutometinibHow we know
- Neoadjuvant Avutometinib/Defactinib and mFOLFIRINOX Combination Therapy in Pancreatic AdenocarcinomaNot yet recruitingPhase 1/2University of VirginiaNCT07824960Written as Avutometinib (VS-6766) + Defactinib (VS-6063)How we know
- Phase Ib Study of Avutometinib, Defactinib, and Everolimus in RAS Pathway Mutant Endometrial CancerRecruitingPhase 1M.D. Anderson Cancer CenterNCT07318324Written as AvutometinibHow we know
- VS-6766+Abema+Fulv in Met HR+/HER- BCRecruitingPhase 1/2Adrienne G. WaksNCT05608252Written as VS-6766How we know
- Stereotactic Body Radiotherapy Plus FAK and RAF/MEK Inhibition in Advanced Pancreatic AdenocarcinomaRecruitingPhase 2Washington University School of MedicineNCT07126158Written as AvutometinibHow we know
- Defactinib, Avutometinib and Nivolumab for the Treatment of Anti-PD1 Refractory LKB1-Mutant Advanced Non-Small Cell Lung CancerRecruitingPhase 2Emory UniversityNCT06495125Written as AvutometinibHow we know
- 5G-RUBY: Avutometinib and Defactinib in Malignant Brain TumoursRecruitingPhase 1/2Institute of Cancer Research, United KingdomNCT06630260Written as AvutometinibHow we know
- Defactinib and Avutometinib, With or Without Encorafenib, for the Treatment of Patients With Brain Metastases From Cutaneous MelanomaRecruitingPhase 1/2University of UtahNCT06194929Written as AvutometinibHow we know
- A Phase 2 Study of Avutometinib (VS-6766) Plus DefactinibRecruitingPhase 2University of OklahomaNCT05512208Written as Avutometinib (VS-6766) + defactinibHow we know
- A Study of Avutometinib (VS-6766) and Defactinib in People With Mesonephric Gynecologic CancerActive, not recruitingPhase 2Memorial Sloan Kettering Cancer CenterNCT05787561Written as Avutometinib (VS-6766)How we know
- A Study of Avutometinib for People With Solid Tumor CancersCompletedPhase 1Memorial Sloan Kettering Cancer CenterNCT06104488Written as AvutometinibHow we know
- Phase I Trial of VS-6766 Alone and in Combination With EverolimusCompletedPhase 1Royal Marsden NHS Foundation TrustNCT02407509Written as VS-6766How we know
- Study of Avutometinib (VS-6766) + Adagrasib in KRAS G12C NSCLC PatientsCompletedPhase 1/2Verastem, Inc.NCT05375994Written as avutometinib (VS-6766) and adagrasibHow we know
- A Study of VS-6766 and Cetuximab in Patients With Advanced Colorectal CancerSuspendedPhase 1/2University of ChicagoNCT05200442Written as VS-6766/avutometinibHow we know
- Phase I Trial of Defactinib and VS-6766.Active, not recruitingPhase 1Institute of Cancer Research, United KingdomNCT03875820Written as VS-6766How we know
See all 29 studies that test RO5126766 →
Given beside what is tested · 1 — RO5126766 is usual care or a partner of the new treatment
Codes
What other systems call RO5126766 · ClinicalTrials.gg INT006219
- MeSH (NLM) C577924RO5126766One source NLM
- UNII (FDA) D0D4252V97AVUTOMETINIBConfirmed FDA, NLM
| System | Code | Name there | Checked by |
|---|---|---|---|
| MeSH (NLM) | C577924 | RO5126766 | One source NLM |
| UNII (FDA) | D0D4252V97 | AVUTOMETINIB | Confirmed FDA, NLM |
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.